William Blair has recently initiated Applied Therapeutics Inc (APLT) stock to Outperform rating, as announced on July 31, 2024, according to Finviz. Earlier, on March 26, 2024, RBC Capital Mkts had initiated the stock to Outperform, setting a price target of $12. Leerink Partners also initiated Outperform rating with a price target of $12. Additionally, Barclays reduced Equal Weight rating on January 4, 2022, with a target price of $7. Goldman analysts, in their report published on August 27, 2021, also reduced Sell rating and set a price target of $16 for Applied Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Applied Therapeutics Inc (APLT) Stock Trading Recap
On Monday, Applied Therapeutics Inc (APLT) stock saw a modest uptick, ending the day at $10.24 which represents a slight increase of $0.15 or 1.49% from the prior close of $10.09. The stock opened at $10.3 and touched a low of $9.85 during the day, reaching a high of $10.62. The volume of shares traded was 2.18 million falling short of the average volume of 2.58 million.
APLT Stock Performance and Moving Averages
In recent trading, Applied Therapeutics Inc (APLT) stock price has shown some volatility, fluctuating 10.58% over the last five trades and 19.49% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 131.15%, and it has gained 66.50% in the previous three months. Currently, APLT is trading at 12.22%, 29.33%, and 75.90% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, APLT, a Healthcare sector stock, is trading 1.49% below its 52-week high but remains 472.07% above its 52-week low. The Average True Range (ATR) (14 days) of 0.6 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Applied Therapeutics Inc’s Profitability and Valuation Ratios
Applied Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -586.31% and a profit margin of -905.38%, with a gross margin of 131.15%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Applied Therapeutics Inc’s market capitalization stands at $1.23 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 115.79, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 202.21, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 25.12% of Applied Therapeutics Inc (APLT)’s shares, while financial institutions hold 80.02%.
Notable insider trades include Perfetti Riccardo, Chief Medical Officer at Applied Therapeutics Inc (APLT), who sold 22681 shares on Aug 22 ’24, at $5.83 each, totaling $0.13 million. On Aug 13 ’24, Shendelman Shoshana, President and CEO, sold 357423 shares for $6.18 each, amounting to $2.21 million. Additionally, on Aug 12 ’24, Shendelman Shoshana sold 300000 shares at $5.98 each, generating $1.79 million.
